Conjunctivitis News and Research

RSS

Conjunctivitis is an eye infection that may cause redness and discharge from the eye, sometimes with pain or itching. It can be caused by bacteria or viruses.

Researchers find biological evidence linking Zika virus infection and Guillain-Barré syndrome

In a collaborative effort with scientists at six Colombian hospitals, Johns Hopkins Medicine researchers report what they believe to be the strongest biological evidence to date linking Zika virus infection and Guillain-Barré syndrome.

5 Oct 2016

Researchers find genomic material from Zika virus in tears

Researchers have found that Zika virus can live in eyes and have identified genetic material from the virus in tears, according to a study from Washington University School of Medicine in St. Louis.

7 Sep 2016

Mayo Clinic offers CDC’s Zika virus screening test

Mayo Clinic will offer the Zika virus antibody test developed by the Centers for Disease Control and Prevention.

1 Sep 2016

Official statistics may underestimate size of Zika epidemic, study suggests

A study supported by FAPESP and coordinated by researchers at the São José do Rio Preto Medical School in São Paulo State, Brazil, suggests official statistics may underestimate the size of the epidemic caused by Zika virus.

1 Sep 2016

Revised FDA guidance recommends universal testing of entire blood supply for Zika virus in the U.S.

As a further safety measure against the emerging Zika virus outbreak, today the U.S. Food and Drug Administration issued a revised guidance recommending universal testing of donated Whole Blood and blood components for Zika virus in the U.S. and its territories.

27 Aug 2016

Research shows alcohol abuse drug inhibits ocular conjunctival scarring in mouse model

New research from University College London, Moorfields Eye Hospital and Duke University School of Medicine has identified a gene that drives scarring, together with a rapidly translatable therapy, for the UK's most common cause of blinding conjunctivitis.

4 Aug 2016

Shire’s Xiidra receives FDA approval for treating dry eye disease in adult patients

Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.

12 Jul 2016

WHO/PAHO statement on Zika virus and the 2016 Rio Olympic and Paralympic Games

The World Health Organization (WHO) and the Pan American Health Organization (PAHO) recognize that athletes and visitors are seeking more information on the risks of Zika and ways to prevent infection while attending the 2016 Rio Olympic and Paralympic Games (5 August to 18 September 2016).

16 May 2016

More neurological resources needed to manage Zika virus infections

WFN Zika-Info-Service: World Federation of Neurology establishes Work Group on Zika virus to support international efforts - Lack of neurological resources in countries most concerned by the virus.

28 Apr 2016

Duke-NUS study highlights Zika virus structure and behaviour

An important breakthrough in understanding the Zika virus structure and its behaviour has been highlighted in a study by Duke-NUS Medical School scientists.

20 Apr 2016

Zika threat to Olympics attendees? An interview with Prof. Eskild Petersen

The risk in terms of the Olympics, especially for travelling populations remains low – with the notable exception of pregnant women.

31 Mar 2016

Study provides first evidence that Zika virus may cause Guillain-Barré syndrome

Analysis of blood samples from 42 patients diagnosed with Guillain-Barré syndrome (GBS) during the Zika virus outbreak in French Polynesia provides the first evidence that Zika virus might cause GBS, a severe neurological disorder, according to new research published in The Lancet today.

2 Mar 2016

Electronic health records could help identify people who have undiagnosed type 2 diabetes

In 2012, a group of UCLA researchers set out to mine thousands of electronic health records for a more accurate and less expensive way to identify people who have undiagnosed type 2 diabetes. The researchers got much more than they bargained for.

16 Feb 2016

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015.

25 Jan 2016

A Thai man with Zika virus has been hospitalized in Taiwan

A man from Thailand has been hospitalized in Taiwan after having arrived there infected with Zika virus, an agent thought to be associated with brain-damaging birth defects in infants.

21 Jan 2016

Philip Chapper & Co to showcase new partner products at Europe’s largest pharmaceutical trade fair

Philip Chapper & Company Ltd, a UK company with over 40 years’ experience within medical supplies, is to showcase innovative products from new suppliers at the industry’s largest European trade fair.

28 Sep 2015

Significant divide can exist between patients and physicians about same medical terms

Few things are more stressful than dealing with a sick child. From discussing treatment with a pediatrician to complying with day care policies, a parent must consider many factors when making a decision about their child's health. Now, a recent study from the University of Missouri and the University of Michigan is shedding light on the significant divide that can exist between patients and physicians about the same terminology--especially when it comes to discussing "pink eye," a particular flashpoint in childcare.

25 Aug 2015

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million.

3 Aug 2015

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications.

29 Jul 2015

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV.

6 May 2015